234 related articles for article (PubMed ID: 28393427)
1. HnRNPM and CD44s expression affects tumor aggressiveness and predicts poor prognosis in breast cancer with axillary lymph node metastases.
Sun H; Liu T; Zhu D; Dong X; Liu F; Liang X; Chen C; Shao B; Wang M; Wang Y
Genes Chromosomes Cancer; 2017 Aug; 56(8):598-607. PubMed ID: 28393427
[TBL] [Abstract][Full Text] [Related]
2. Expression and significance of CD44s, CD44v6, and nm23 mRNA in human cancer.
Liu YJ; Yan PS; Li J; Jia JF
World J Gastroenterol; 2005 Nov; 11(42):6601-6. PubMed ID: 16425351
[TBL] [Abstract][Full Text] [Related]
3. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing.
Xu Y; Gao XD; Lee JH; Huang H; Tan H; Ahn J; Reinke LM; Peter ME; Feng Y; Gius D; Siziopikou KP; Peng J; Xiao X; Cheng C
Genes Dev; 2014 Jun; 28(11):1191-203. PubMed ID: 24840202
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas.
Berner HS; Suo Z; Risberg B; Villman K; Karlsson MG; Nesland JM
Histopathology; 2003 Jun; 42(6):546-54. PubMed ID: 12786890
[TBL] [Abstract][Full Text] [Related]
5. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.
Zhang FL; Cao JL; Xie HY; Sun R; Yang LF; Shao ZM; Li DQ
Cancer Res; 2018 Oct; 78(20):5780-5792. PubMed ID: 30093560
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous nuclear ribonucleoprotein M promotes the progression of breast cancer by regulating the axin/β-catenin signaling pathway.
Yang WH; Ding MJ; Cui GZ; Yang M; Dai DL
Biomed Pharmacother; 2018 Sep; 105():848-855. PubMed ID: 30021377
[TBL] [Abstract][Full Text] [Related]
7. [Expression tumor stem cell surface marker CD44 in gastric cancer and its significance].
Xie JW; Huang CM; Zheng CH; Li P; Wang JB; Lin JX; Lu J
Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Nov; 16(11):1107-12. PubMed ID: 24277411
[TBL] [Abstract][Full Text] [Related]
8. CD44 isoforms are heterogeneously expressed in breast cancer and correlate with tumor subtypes and cancer stem cell markers.
Olsson E; Honeth G; Bendahl PO; Saal LH; Gruvberger-Saal S; Ringnér M; Vallon-Christersson J; Jönsson G; Holm K; Lövgren K; Fernö M; Grabau D; Borg A; Hegardt C
BMC Cancer; 2011 Sep; 11():418. PubMed ID: 21957977
[TBL] [Abstract][Full Text] [Related]
9. hnRNPM, a potential mediator of YY1 in promoting the epithelial-mesenchymal transition of prostate cancer cells.
Yang T; An Z; Zhang C; Wang Z; Wang X; Liu Y; Du E; Liu R; Zhang Z; Xu Y
Prostate; 2019 Aug; 79(11):1199-1210. PubMed ID: 31251827
[TBL] [Abstract][Full Text] [Related]
10. The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy.
Noordzij MA; van Steenbrugge GJ; Verkaik NS; Schröder FH; van der Kwast TH
Clin Cancer Res; 1997 May; 3(5):805-15. PubMed ID: 9815753
[TBL] [Abstract][Full Text] [Related]
11. CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients.
Li Z; Chen K; Jiang P; Zhang X; Li X; Li Z
Diagn Pathol; 2014 Apr; 9():79. PubMed ID: 24708709
[TBL] [Abstract][Full Text] [Related]
12. IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.
Hu S; Wu X; Zhou B; Xu Z; Qin J; Lu H; Lv L; Gao Y; Deng L; Yin J; Li G
J Cancer Res Clin Oncol; 2014 Jun; 140(6):883-93. PubMed ID: 24647926
[TBL] [Abstract][Full Text] [Related]
13. Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion.
Afify A; Purnell P; Nguyen L
Exp Mol Pathol; 2009 Apr; 86(2):95-100. PubMed ID: 19167378
[TBL] [Abstract][Full Text] [Related]
14. Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors.
Afify AM; Tate S; Durbin-Johnson B; Rocke DM; Konia T
Int J Biol Markers; 2011; 26(1):50-7. PubMed ID: 21279958
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of CD44s, CD44v3 and CD44v6 in breast cancer.
Wu XJ; Li XD; Zhang H; Zhang X; Ning ZH; Yin YM; Tian Y
J Int Med Res; 2015 Apr; 43(2):173-9. PubMed ID: 25571897
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of CD44 variants expression in colorectal cancer.
Li XD; Ji M; Wu J; Jiang JT; Wu CP
Tumori; 2013; 99(1):88-92. PubMed ID: 23549006
[TBL] [Abstract][Full Text] [Related]
17. CD44v6 expression in primary breast carcinoma in western India: a pilot clinicopathologic study.
Shah NG; Trivedi TI; Vora HH; Patel KC; Tankshali R; Goswami JV; Shukla SN; Shah PM
Tumori; 2010; 96(6):971-7. PubMed ID: 21388061
[TBL] [Abstract][Full Text] [Related]
18. Expression of CD44 and variant proteins in human colorectal cancer and its relevance for prognosis.
Ropponen KM; Eskelinen MJ; Lipponen PK; Alhava E; Kosma VM
Scand J Gastroenterol; 1998 Mar; 33(3):301-9. PubMed ID: 9548625
[TBL] [Abstract][Full Text] [Related]
19. Role of CD44 in nonpalpable T1a and T1b breast cancer.
Lyzak JS; Yaremko ML; Recant W; Baunoch DA; Joseph L
Hum Pathol; 1997 Jul; 28(7):772-8. PubMed ID: 9224743
[TBL] [Abstract][Full Text] [Related]
20. PTEN/PI3K/AKT protein expression is related to clinicopathological features and prognosis in breast cancer with axillary lymph node metastases.
Wang LL; Hao S; Zhang S; Guo LJ; Hu CY; Zhang G; Gao B; Zhao JJ; Jiang Y; Tian WG; Wang J; Luo DL
Hum Pathol; 2017 Mar; 61():49-57. PubMed ID: 27864123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
